Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.46 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.46 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL49205 | 0.83 | PIK3CD (0.51) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL48896 | 0.79 | PIK3CD (0.62) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL1545920 | 0.78 | PIK3CD (0.52) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL27615727 | 0.76 | PIK3CD (0.46) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL48903 | 0.74 | PIK3CD (0.57) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL48726 | 0.72 | PIK3CD (0.60) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL48834 | 0.71 | PIK3CD (0.58) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL48595 | 0.71 | PIK3CD (0.53) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL48625 | 0.71 | PIK3CD (0.67) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL48463 | 0.70 | PI4KB (0.60) | PIK3CDPIK3CGPI4KBPIK3CAPIK3C2G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | PIK3CD 4/4885PIK3CG 8/4885PI4KB 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.